South & Central America Infectious Disease Therapeutics Market

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2030

Analysis - by Drug Class (Anti-viral, Anti-Bacterial, Anti-Fungal, and Others), Indication (HIV, Hepatitis, Tuberculosis, Influenza, HPV, and Others), Route Of Administration (Oral, Parenteral, Topical, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others)

No. of Pages: 90
Report Code: BMIRE00030547
Category: Life Sciences
South & Central America Infectious Disease Therapeutics Market
Buy Now

The South & Central America infectious disease therapeutics market was valued at US$ 6,252.96 million in 2022 and is expected to reach US$ 8,167.05 million by 2030; it is estimated to register a CAGR of 3.4% from 2022 to 2030.

Growing Opportunities in Developing Nations Fuels South & Central America Infectious Disease Therapeutics Market

The growing incidence of infectious diseases is anticipated to increase the sales of infectious disease therapeutics drugs in developing countries. In addition, high investments in health research and life science in emerging countries play a key role in promoting the latest technologies in developing countries, which, in turn, supports the inclination toward infectious disease diagnosis and treatment. For instance, UNAIDS is calling for an investment of US$ 29 billion by 2025 to meet the needs of low- and middle-income countries in the AIDS response. Thus, crucial infectious disease therapeutics product manufacturers in emerging infectious disease therapeutics markets in Brazil are expected to witness lucrative opportunities in the future. This is owing to the high prevalence of infectious diseases such as Hepatitis, HAI, HIV, and influenza; a large population of patients; a rise in disposable income of the population; improving infrastructure of healthcare; and growing medical tourism in these countries.

South & Central America Infectious Disease Therapeutics Market Overview

The infectious disease therapeutics market in South & Central America is sub segmented into Brazil, Argentina, and the Rest of South & Central America. The infectious disease therapeutics market in South & Central America is expected to grow due to increased prevalence of infectious diseases, surge in research activities, and rising healthcare expenditure by the regional countries. Brazil has made huge progress in the healthcare sector owing to expanding healthcare expenditure. According to the International Trade Administration, Brazil spends ~9.1% of its GDP on healthcare and is the major healthcare market in Latin America. The infectious disease therapeutics market in Brazil is estimated to boom owing to the increasing prevalence of infectious diseases.

Infectious diseases are still significant causes of death in Brazil. A survey revealed that a high burden of infectious disease was observed among men and children under 5 years of age, mainly due to HIV/AIDS. According to the data provided by the Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2022, around 990,000 people were living with HIV and AIDS in Brazil. Thus, owing to the abovementioned factors, the infectious disease therapeutics market in Brazil is anticipated to grow during the forecast period.

South & Central America Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
south-and-central-america-infectious-disease-therapeutics-market-img1

South & Central America Infectious Disease Therapeutics Market Segmentation 

The South & Central America infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.

Based on drug class, the South & Central America infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.

In terms of indication, the South & Central America infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.

Based on route of administration, the South & Central America infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.

In terms of distribution channel, the South & Central America infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.

By country, the South & Central America infectious disease therapeutics market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America infectious disease therapeutics market share in 2022.

AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc, Merck & Co Inc, and Pfizer Inc are some of the leading companies operating in the South & Central America infectious disease therapeutics market.

South & Central America Infectious Disease Therapeutics Market Strategic Insights

global-market-strategic-framework
Get more information on this report

South & Central America Infectious Disease Therapeutics Market Segmentation Analysis

South & Central America Infectious Disease Therapeutics Market Report Highlights

South & Central America Infectious Disease Therapeutics Report Scope

Report Attribute Details
Market size in 2022 US$ 6,252.96 Million
Market Size by 2030 US$ 8,167.05 Million
CAGR (2022 - 2030) 3.4%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By Drug Class
  • Anti-viral
  • Anti-Bacterial
  • Anti-Fungal
By Indication
  • HIV
  • Hepatitis
  • Tuberculosis
  • Influenza
  • HPV
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
Regions and Countries Covered South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Market leaders and key company profiles
  • AbbVie Inc
  • Astellas Pharma Inc
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • GSK Plc
  • Merck & Co Inc
  • Pfizer Inc
Get more information on this report

South & Central America Infectious Disease Therapeutics Market Country and Regional Insights

south-and-central-america-infectious-disease-therapeutics-market
Get more information on this report

The List of Companies - South & Central America Infectious Disease Therapeutics Market

1. AbbVie Inc
2. Astellas Pharma Inc
3. Bayer AG
4. F. Hoffmann-La Roche Ltd
5. Gilead Sciences Inc
6. GSK Plc 
7. Merck & Co Inc 
8. Pfizer Inc

Frequently Asked Questions
How big is the South & Central America Infectious Disease Therapeutics Market?

The South & Central America Infectious Disease Therapeutics Market is valued at US$ 6,252.96 Million in 2022, it is projected to reach US$ 8,167.05 Million by 2030.

What is the CAGR for South & Central America Infectious Disease Therapeutics Market by (2022 - 2030)?

As per our report South & Central America Infectious Disease Therapeutics Market, the market size is valued at US$ 6,252.96 Million in 2022, projecting it to reach US$ 8,167.05 Million by 2030. This translates to a CAGR of approximately 3.4% during the forecast period.

What segments are covered in this report?

The South & Central America Infectious Disease Therapeutics Market report typically cover these key segments-

  • Drug Class (Anti-viral, Anti-Bacterial, Anti-Fungal)
  • Indication (HIV, Hepatitis, Tuberculosis, Influenza, HPV)
  • Distribution Channel (Hospital Pharmacies, Retail Pharmacies)

What is the historic period, base year, and forecast period taken for South & Central America Infectious Disease Therapeutics Market?

The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South & Central America Infectious Disease Therapeutics Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2030
  • Who are the major players in South & Central America Infectious Disease Therapeutics Market?

    The South & Central America Infectious Disease Therapeutics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • AbbVie Inc
  • Astellas Pharma Inc
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • GSK Plc
  • Merck & Co Inc
  • Pfizer Inc
  • Who should buy this report?

    The South & Central America Infectious Disease Therapeutics Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the South & Central America Infectious Disease Therapeutics Market value chain can benefit from the information contained in a comprehensive market report.

    Available Report Formats

    pdf-format excel-format pptx-format
    Buy Now

    Customization Form

    Please tell us your area of interest
    (Market Segments/ Regions and Countries/ Companies)